Check-Cap Medical (CHEK) - Cumulative Company Assets

Check-Cap Ltd. (CHEK) is advancing oncology diagnostics, overcoming the complexities of Israeli jurisdiction and logistical disruptions through global agreements and patent protection in the US. The business is countering pressure from more affordable genetic tests by promoting innovative capsules. Total assets amount to 0.00. The daily price action shown below confirms the electronics manufacturing outsourcing strategy, allowing the company to focus on engineering development.

CHEK: Check-Cap Ltd. Aggregate Company Assets 07/04/2022 - 11/28/2025

Analytical breakdowns for check-cap.com (CHEK)

- price and consensus price forecast:

Stock Price Check-Cap|CHEK - Analyst Consensus Forecast

- market capitalization data:

Market Valuation CHEK|CHEK - Enterprise Value

- book capitalization data:

Book Value per Share Check-Cap|CHEK - Company Book Value|Capitalization to Book Value Ratio check-cap.com|CHEK - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Check-Cap Ltd.|CHEK - Long-Term Debt to Capital|Current Liabilities to Capital Check-Cap|CHEK - Company Debts|Debt to Net Assets Ratio CHEK

Analysis of all company metrics:CHEK, Check-Cap Medical

The prospects for Check-Cap Ltd. (CHEK) depend on the commercialization of non-invasive cancer screening, which requires significant resources for clinical trials and implementation. The trend in total assets, calculated reverse-engineered via ROA, reflects the aggregate volume of capital and liabilities, allowing investors to assess the business's actual material base and avoid overpaying for an unjustifiably high market capitalization backed by an empty balance sheet.

Competitors of Check-Cap Ltd. (CHEK)